PSG1 Tendon Injection to Enhance MSC-Driven Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tendon injuries, such as tendonitis and tendinopathy, are inadequate in promoting effective healing and regeneration, particularly in enhancing the migration of mesenchymal stem cells to the injury site.
Innovation Solution
The use of pregnancy-specific glycoproteins (PSG1) and mesenchymal stem cells (MSCs), either co-administered or separately, to enhance tendon healing by promoting MSC migration and regeneration. Administration methods include intra-tendon or peri-tendon injection, topical formulations, and transfection of MSCs with PSG1 expression vectors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for tendon injuries, then current standard care is provided, but effective healing and regeneration is not promoted
Solution Approach 1:
The patent combines PSG1 protein therapy with mesenchymal stem cell (MSC) therapy to treat tendon injuries. The PSG1 protein enhances MSC migration to the injury site and promotes tendon regeneration, creating a synergistic effect that improves healing effectiveness beyond what either treatment achieves alone.
Solution Approach 2:
PSG1 acts as a mediator protein that facilitates the interaction between MSCs and the tendon injury site. It enhances MSC migration, survival, and differentiation into tendon-specific cells, thereby promoting effective healing and regeneration.
2Reliability
If PSG1 and MSCs are co-administered, then tendon healing is enhanced, but treatment complexity increases
Solution Approach 1:
The treatment can be segmented into separate administration of PSG1 protein and MSCs, or combined administration depending on clinical needs. The PSG1 protein can be administered alone as a preliminary treatment to prepare the injury site, followed by MSC injection, or both can be administered together in a single procedure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances tendon healing by improving MSC migration to the injury site, potentially halting, slowing, or reversing tendon degeneration, and providing symptomatic relief for tendon pain and stiffness.
Implementation Method 1
The Applicant has discovered that a pregnancy-specific glycoprotein (for example PSG1) enhances the migration of mesenchymal stem cells (MSCs).
Implementation Method 2
PSG1 is involved in activation of transforming growth factor-β 1 (TGFß1), a cytokine essential to suppression of inflammatory T-cells
Implementation Method 3
important for differentiation of tolerance inducing CD4+CD25+FoxP3+ regulatory T cells (Tregs), a cell population shown to be important in the prevention of Graft versus Host Disease (GvHD)
Data Source
AI summary
The use of Fc-tagged Pregnancy-specific glycoprotein 1 (PSG1-Fc) in a method of treatment of a tendon injury in a human, in which the PSG1 is administered by intra-tendon or peri-tendon injection, is described. Also described is the use of CC49 in a method of treatment of tendonitis, tendinosis, tendinopathy, or tendon damage in an equine mammal, in which the CC49 is administered by intra-tendon or peri-tendon injection.